Covid-19 Vaccine Responsiveness in MM and Waldenstrom
This research is being done to see if the immune (defense) system of people with Multiple Myeloma and Waldenstrom's Macroglobulinemia reacts to the COVID-19 vaccine.
Checked against the public recordLast updated Nov 26, 2025 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Massachusetts General Hospital
- Interventions being studied
- Not specified
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Age \>18 years. * Lack of a contra-indication to a currently available COVID-19 vaccine. * Diagnosis of MM according to International Myeloma Working Group (IWMG) criteria (Cohort 1) or Diagnosis of WM according to WHO criteria (Cohort 2) * For treatment naïve WM patients (Cohort 2A): * Patient must have no prior history of anticancer treatment for WM. * The treating investigator must have no intention to initiate WM therapy within 2 months * For WM patients receiving BTK inhibitor (Cohort 2B): * Patient must have no history of cytotoxic chemotherapy within 1 year, and no history of other anticancer therapy within 6 months. * For currently or previously treated WM patients (Cohort 2C): * Patient must not be currently taking a BTK inhibitor or had recent exposure within 1 month of enrollment. Current or prior history of any other WM-directed therapy is allowed. Exclusion Criteria: \-
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Brigham and Women's HospitalBoston, Massachusetts
- Dana-Farber Cancer InstituteBoston, Massachusetts
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 26, 2025. Always confirm current availability with the study team.